Rezheen J. Rashid, Khanda A. Anwar, Ayoob A. Mohammed, Soran H. Tahir, Ali H. Hasan, Snur Othman, Ismael Y. Abdullah, Sasan M. Ahmed and 5 more
Introduction Due to its rarity, there is limited information regarding breast hydatid disease, mostly derived from case reports. This study aims to review the clinical presentation and management of the disease systematically. Methods The PubMed/Medline and Google Scholar were searched with the following keywords…
Rezheen J. Rashid, Khanda A. Anwar, Ayoob A. Mohammed, Soran H. Tahir, Ali H. Hasan, Snur Othman, Ismael Y. Abdullah, Sasan M. Ahmed and 5 more
IntroductionDue to its rarity, there is limited information regarding breast hydatid disease, mostly derived from case reports. This study aims to review the clinical presentation and management of the disease systematically.
MethodsThe PubMed/Medline and Google Scholar were searched with the following keywords: (Breast OR Breasts OR "mammary gland" AND hydatid OR hydatidosis OR echinococcus OR echinococcal OR echinococcosis OR "E. granulosus"). Only English-language studies published in legitimate journals were included. Additional inclusion criteria involved a confirmed diagnosis of breast hydatid cyst, details on presentation, cyst characteristics, and management.
ResultsMost cases were reported in India (32.6%) and Turkey (25.6%). The mean age of the patients was 40.88 ± 15.7 years, and all 43 patients were female. Most (69.8%) were asymptomatic, while 25.6% reported pain and 2.3% reported dry skin. Surgery with albendazole was the treatment of choice in 51.2% of the cases, followed by surgery alone in 39.5%. Most cases (65.1%) recovered without complications, whereas one did not and was under follow-up. The recovery status was not mentioned in 14 cases (32.6%).
ConclusionBreast hydatid cyst is an extremely rare finding that can be asymptomatic in most instances. Surgery combined with albendazole may be the most successful treatment approach.
Hiwa O. Abdullah, Berun A. Abdalla, Fahmi H. Kakamad, Jafaar O. Ahmed, Hiwa O. Baba, Marwan N. Hassan, Rawa Bapir, Hawbash M. Rahim and 13 more
Predatory journals challenge the scholarly community by muddling the boundary between legitimate and dubious publishing practices. Despite the awareness of predatory publishers, there are no globally accepted criteria for identifying them. Various warning lists have emerged as predatory practices evolve, but they are…
Predatory Publishing Lists: A Review on the Ongoing Battle Against Fraudulent Actions
Hiwa O. Abdullah, Berun A. Abdalla, Fahmi H. Kakamad, Jafaar O. Ahmed, Hiwa O. Baba, Marwan N. Hassan, Rawa Bapir, Hawbash M. Rahim and 13 more
Predatory journals challenge the scholarly community by muddling the boundary between legitimate and dubious publishing practices. Despite the awareness of predatory publishers, there are no globally accepted criteria for identifying them. Various warning lists have emerged as predatory practices evolve, but they are not impervious to criticism despite their utility. This study reviewed the most common of the predatory lists. Beall's list, the pioneer in exposing predatory publishers, received criticism for its inclusion criteria. It is now anonymously managed and poorly updated. Cabells' list has a broad range of inclusion criteria; however, some have been criticized for redundancy and lack of alignment with predatory practices. Kscien's list shows promise as an alternative for spotting predatory journals and publishers. However, it requires refinement since the included journals, based on their core criteria, are not distinguished from those included using traditional criteria. The Early Warning List of International Journals is a recent compilation with diverse criteria. Despite attracting the scientific community's attention, there are questions about the reliability of its inclusion criteria. However, these lists are crucial in flagging predatory publishers; researchers can depend on them while preparing their manuscripts.
Hamdi Yahya Al Turkey, Aland S. Abdullah, Harem K. Ahmed, Bnar J. Hama Amin, Yousif M. Mahmood, Suhaib H. Kakamad, Aso N. Qadir, Hemin S. Mohammed and 6 more
Introduction Post-COVID-19 Pulmonary Fibrosis (PC-19-PF) is among the complications following COVID-19. It is the complication that is associated with the most amount of long-term impact on the respiratory system. Different physicians approach management in different ways; therefore, we conduct a study to neatly…
Post COVID-19 Pulmonary Fibrosis Management: A Systematic Review
Hamdi Yahya Al Turkey, Aland S. Abdullah, Harem K. Ahmed, Bnar J. Hama Amin, Yousif M. Mahmood, Suhaib H. Kakamad, Aso N. Qadir, Hemin S. Mohammed and 6 more
IntroductionPost-COVID-19 Pulmonary Fibrosis (PC-19-PF) is among the complications following COVID-19. It is the complication that is associated with the most amount of long-term impact on the respiratory system. Different physicians approach management in different ways; therefore, we conduct a study to neatly summarize all the different management and their possible outcomes.
MethodsThe databases that were searched included CINAHL, PubMed/MEDLINE, Cochrane Library, Web of Science, and EMBASE to identify English language studies published up to October 5th, 2023.
ResultsInitially, the systematic search conducted brought 150 papers. Out of the 150, 13 of them were included in this study. A total of 662 patients were included in the study, all with different managements for COVID-19-induced pulmonary fibrosis. The mean age was 61.8 years. Many comorbidities were observed in patients with COVID-19-induced pulmonary fibrosis. Different treatment regimens were picked based on the different conditions of the patients but as far as antifibrotics go, Pirfenidone and Nintedanib were the most commonly used ones.
ConclusionBoth antifibrotics and steroids seemed to yield justifiable outcomes when used separately as well as when used in combination.
Sami S. Omar, Rebaz Haji Ali, Shalaw H. Abdullah, Dlsoz M. Hussein, Belan Mikaeil M. Radha, Alaa B. Latif, Shano M. Ali, Dilan S. Hiwa and 11 more
Abstract Introduction Mesothelioma is a rare and rapidly advancing tumor that usually emerges on the mesothelial surfaces of the pleura or peritoneum. Despite being a well-recognized rare disease for decades, the only approved primary treatment protocol has been platinum-based treatments plus pemetrexed, whether or…
Role of Durvalumab (Anti-PD-L1) in the Management of Mesothelioma: A Systematic Review of the Current Literature
Sami S. Omar, Rebaz Haji Ali, Shalaw H. Abdullah, Dlsoz M. Hussein, Belan Mikaeil M. Radha, Alaa B. Latif, Shano M. Ali, Dilan S. Hiwa and 11 more
Introduction Mesothelioma is a rare and rapidly advancing tumor that usually emerges on the mesothelial surfaces of the pleura or peritoneum. Despite being a well-recognized rare disease for decades, the only approved primary treatment protocol has been platinum-based treatments plus pemetrexed, whether or not bevacizumab is administered. Immunotherapy-based immune checkpoint inhibitors demonstrated a promising antitumor efficacy in a variety of cancer types. This is a systematic review of the current role of durvalumab in the management of this condition.
Methods A systematic search was carried out through the databases and search engines. Regardless of study design, line of therapy, mode of therapy, or Eastern Cooperative Oncology Group (ECOG) performance status, studies that primarily focused on the outcomes of treating this disease with durvalumab were eligible for inclusion. After the initial and full-text screenings, five studies were reviewed.
Results The median age of the total 235 patients was 66.9 years. Males comprised 174 (74.04%) of the cases, with 61 (25.95%) cases being female. The Epithelioid mesothelioma subtype accounted for 194 (82.55%) of the patients. Durvalumab, in combination with pemetrexed cisplatin/carboplatin as therapy, was used in 109 (48.38%) cases. Durvalumab and tremelimumab were used in the treatment of 40 (17.02%) cases, of which 17 (7.23%) had retreatment with both immunotherapies. Among the patients who underwent durvalumab treatment, 69 (29.36% ) of the individuals previously received carboplatin/pemetrexed and cisplatin/pemetrexed.
Conclusion Durvalumab can be utilized as an effective alternative for malignant pleural mesothelioma treatment, providing positive results and acceptable safety profiles.
